Federated Hermes’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Federated Hermes’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-17,847	Closed	-$189K	–	2307
2022 Q4	$189K	Buy	+17,847	New	+$144K	﹤0.01%	1567
2021 Q1	–	Sell	-131	Closed	-$2K	–	2387
2020 Q4	$2K	Buy	131 +111	+555%	+$1.66K	﹤0.01%	2141
2020 Q3	$1K	Sell	20 -104	-84%	-$1.31K	﹤0.01%	2220
2020 Q2	$2K	Buy	+124	New	+$1.57K	﹤0.01%	2110
2020 Q1	–	Sell	-105	Closed	-$2K	–	2393
2019 Q4	$2K	Buy	+105	New	+$936	﹤0.01%	2052

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Federated Hermes's PRVB Position: Q1 2023 in Review

Federated Hermes sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 17,847 shares — an estimated $189K sold.

Federated Hermes first reported a position in PRVB in Q4 2019 and held it in 5 quarters. The position peaked at $189K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

Federated Hermes reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Federated Hermes sold 17,847 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $189K.
Federated Hermes first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
Federated Hermes's Provention Bio, Inc. Common Stock position peaked at $189K in Q4 2022.
182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.